Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Treatment Study of Non-Metastatic Desmoplastic Medulloblastoma in Children

Clinical Trial Title: 
A phase II study for the treatment of non-metastatic desmoplastic medulloblastoma in children less than 4 years of age.
Clinical Trial Protocol ID: 
16050507-CAOl
Clinical Trial Investigator Name: 
Mary Lou Schmidt, MD
Clinical Trial Protocol Description: 

The ACNS 1221 study is a single arm multi institutional trial for newly diagnosed young children (0- <4 years of age at study enrollment) with nodular desmoplastic or medulloblastoma with extensive nodularity (MO ND/MBEN medulloblastoma). The primary objective is estimating the progression-free survival distribution associated with treatment as per HITSKK 2000 protocol without intraventricular methotrexate.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are less than 48 months old (4 years of age) at time of definitive surgery.
  • Have been newly diagnosed and have a confirmed histologic diagnosis of nodular desmoplastic (NO) medulloblastoma or medulloblastoma with extensive nodularity (MBEN) from rapid central pathology screening review.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Pediatric Cancers and Blood Disorders
Contact Phone: 
(312) 355-0741
Contact Name: 
Nitin Sane